The Foundation Fighting Blindness (FFB) recently announced it is partnering with 4D Molecular Therapeutics (4DMT) — a discoverer and product developer of adeno-associated virus (AAV) gene therapy vector — to develop intravitreal gene therapeutics for patients with retinal diseases.
Under the terms of the agreement, 4DMT will reportedly provide access to its vector technology, development expertise and manufacturing capabilities while FFB will identify potential academic and business collaborators, provide drug development expertise and fund approved projects to develop transformative gene therapy products.
According to FFB, new vector technologies are critical to the successful use of gene therapies for inherited retinal degenerations (IRD) in order to improve targeting to affected cells within the retina, and to maximize efficacy and safety.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Foundation Fighting Blindness